Target diversity in the CAR NK and CAR NKT pipeline: Data Byte

Developers of CAR NK and CAR NKT cell therapies for cancer are collectively casting a wide net, with the roughly two dozen programs in development mapping to at least 10 targets across both solid and hematologic tumors.

Compared with CAR T cells, CAR NK cells have advantages of built-in off-the-shelf manufacturing and fewer safety risks. As part of the innate immune response, NK cells do not release the same burst of cytokines upon activation as T cells do and are unlikely to cause cytokine release syndrome (CRS) or neurotoxicity after infusion. ...